Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 5, 2015

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Lymphoma, Non-HodgkinLymphoma
Interventions
DRUG

Carfilzomib

"Given IV; Dose Level (DL)~Twice Weekly:~DL -1 and DL 1: 15 mg/m\^2~Weekly:~DL 1.5: 20,27,27 mg/m\^2, DL 2: 20,36,36 mg/m\^2, DL 3: 20,56,56 mg/m\^2 DL 4: 20,70,70 mg/m\^2"

DRUG

Bendamustine

"Given IV; Dose Level (DL)~DL -1: 75 mg/m\^2 DL 1,1.5, 2, 3, and 4: 90 mg/m\^2"

DRUG

Rituximab

Given IV; 375 mg/m\^2

Trial Locations (3)

92093

University of California, San Diego, San Diego

94143

University of California, San Francisco, San Francisco

95616

University of California, Davis, Davis

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

University of California, San Francisco

OTHER

NCT02187133 - Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter